US approves drug for two pediatric mental disorders

	Tweet

Johnson & Johnson won U.S. approval to promote its drug, Risperdal, for two psychiatric conditions in children, U.S. health officials said on Wednesday.

The Food and Drug Administration said it cleared Risperdal for treating schizophrenia in adolescents ages 13 to 17 and for the short-term treatment of manic or mixed episodes of bipolar disorder in ages 10 to 17. 

The drug is the first atypical antipsychotic drug approved to treat either disorder in those age groups, the FDA said.

Risperdal already is sold for treating schizophrenia and acute bipolar episodes in adults, as well as irritability associated with autism in children ages 5 to 16.

J&J currently reaps global annual sales of more than $4 billion from Risperdal and a newer treatment called Invega that is derived from the active ingredient of Risperdal.

(Reporting by Lisa Richwine)

RELATED STORIES:
Barr to resubmit contraceptive for FDA approval   Thalidomide OK for severe childhood arthritis   “Miracle” Cancer Drug Gleevec Can be Toxic to the Heart   New benefit found from blood pressure drug   Complementary medicines can be dangerous for children   Preemies Face Higher Death Rates as Young Adults   Cholesterol meds highlight conflict of interest debate in medicine   Abdominal fat at middle age associated with greater risk of dementia   Children in good shape have better appetite control and energy expenditure   Kids Who Are Sick Have Fewer Friends   Short-Term Celebrex Safe Against Cirrhosis   Why Older People are Generally Less Astute Drivers and How the Answer Could Help Us Understand Schizophrenia and Depression

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]